Search

Your search keyword '"Cotton, Mark F."' showing total 264 results

Search Constraints

Start Over You searched for: Author "Cotton, Mark F." Remove constraint Author: "Cotton, Mark F." Database Unpaywall Remove constraint Database: Unpaywall
264 results on '"Cotton, Mark F."'

Search Results

2. CONTRIBUTORS

3. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study

4. Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age

5. Early Proteomic and Innate Immunity Profiles: A Footprint of Increased Mortality Risk In Infants Living with Hiv From Three African Countries

6. Maternal and birth outcomes in pregnant people with and without HIV in the Western Cape, South Africa

7. Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis

10. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

12. The largest HIV-1-infected T cell clones in children on long-term combination antiretroviral therapy contain solo LTRs

15. Correction to: Similar cortical morphometry trajectories from 5 to 9 years in children with perinatal HIV who started treatment before age 2 years and uninfected controls

16. Optimal dosing of gliclazide—A model‐based approach

17. Associations of HIV and iron status with gut microbiota composition, gut inflammation and gut integrity in South African school‐age children: a two‐way factorial case–control study

20. Maternal ART throughout gestation prevents caudate volume reductions in neonates who are HIV exposed but uninfected

24. High Mortality Following Early Initiation of Antiretroviral Therapy in Infants Living with HIV from Three African Countries

25. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

29. Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial

31. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

32. Antiretroviral choice and severe disease predict poorer neuropsychological outcomes in HIV+ children from Africa

34. Multimodal magnetic resonance neuroimaging measures characteristic of early cART ‐treated pediatric HIV : A feature selection approach

35. Host transcriptomic signatures of tuberculosis can predict immune reconstitution inflammatory syndrome in HIV patients

36. Population pharmacokinetics of ethambutol in African children: a pooled analysis

40. The Impact of Interventions to Prevent Neonatal Healthcare-associated Infections in Low- and Middle-income Countries: A Systematic Review

41. Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure

42. An analysis of the HIV testing cascade of a group of HIV-exposed infants from birth to 18 months in peri-urban Khayelitsha, South Africa

43. The effect of oral iron supplementation on the gut microbiota, gut inflammation, and iron status in iron-depleted South African school-age children with virally suppressed HIV and without HIV

44. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study

46. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

49. Contributors

Catalog

Books, media, physical & digital resources